AU2022286333A1 - Peptides and methods of use - Google Patents

Peptides and methods of use Download PDF

Info

Publication number
AU2022286333A1
AU2022286333A1 AU2022286333A AU2022286333A AU2022286333A1 AU 2022286333 A1 AU2022286333 A1 AU 2022286333A1 AU 2022286333 A AU2022286333 A AU 2022286333A AU 2022286333 A AU2022286333 A AU 2022286333A AU 2022286333 A1 AU2022286333 A1 AU 2022286333A1
Authority
AU
Australia
Prior art keywords
seq
dose
administered
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022286333A
Other languages
English (en)
Other versions
AU2022286333A9 (en
Inventor
Kenji Cunnion
Neel K. Krishna
Ulrich Thienel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Realta Life Sciences Inc
Original Assignee
Realta Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Life Sciences Inc filed Critical Realta Life Sciences Inc
Publication of AU2022286333A1 publication Critical patent/AU2022286333A1/en
Publication of AU2022286333A9 publication Critical patent/AU2022286333A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/12011—Astroviridae
    • C12N2770/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022286333A 2021-06-01 2022-05-31 Peptides and methods of use Pending AU2022286333A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163195401P 2021-06-01 2021-06-01
US63/195,401 2021-06-01
US202163279423P 2021-11-15 2021-11-15
US63/279,423 2021-11-15
PCT/US2022/031559 WO2022256304A1 (en) 2021-06-01 2022-05-31 Peptides and methods of use

Publications (2)

Publication Number Publication Date
AU2022286333A1 true AU2022286333A1 (en) 2023-11-02
AU2022286333A9 AU2022286333A9 (en) 2023-11-16

Family

ID=84323526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022286333A Pending AU2022286333A1 (en) 2021-06-01 2022-05-31 Peptides and methods of use

Country Status (10)

Country Link
US (1) US20240209036A1 (https=)
EP (1) EP4346866A4 (https=)
JP (1) JP2024522988A (https=)
KR (1) KR20240016323A (https=)
AU (1) AU2022286333A1 (https=)
BR (1) BR112023024988A2 (https=)
CA (1) CA3215620A1 (https=)
IL (1) IL308683A (https=)
MX (1) MX2023014326A (https=)
WO (1) WO2022256304A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094372A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10005818B2 (en) * 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
JP6698276B2 (ja) * 2012-01-16 2020-05-27 アトックス バイオ リミテッド 細菌感染の治療用の合成ペプチド
LT3286181T (lt) * 2015-04-22 2021-04-26 Rigel Pharmaceuticals, Inc. Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
EP3740074B1 (en) * 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Also Published As

Publication number Publication date
EP4346866A4 (en) 2025-03-19
CA3215620A1 (en) 2022-12-08
KR20240016323A (ko) 2024-02-06
AU2022286333A9 (en) 2023-11-16
IL308683A (en) 2024-01-01
JP2024522988A (ja) 2024-06-25
BR112023024988A2 (pt) 2024-02-20
MX2023014326A (es) 2023-12-13
EP4346866A1 (en) 2024-04-10
WO2022256304A1 (en) 2022-12-08
US20240209036A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
AU2002336783B2 (en) Cyclic peptides as G-protein-coupled receptor antagonists
US20210047371A1 (en) Peptide compounds to regulate the complement system
JP6915034B2 (ja) 補体活性の変調剤
EP2379584A1 (en) Soluble polypeptides for use in treating autoimmune and inflammatory disorders
AU2021202648A1 (en) Modulation of cellular stress
US7923014B2 (en) Expression and purification of HIP/PAP and uses therefor
CN110087668A (zh) 补体活性的调节剂
US20240209036A1 (en) Peptides and methods of use
JP2026065064A (ja) ペプチドおよび使用方法
CA2954076C (en) Kv1.3 potassium channel antagonists
US20230414506A1 (en) Peptide formulations and methods of use
CN117396215A (zh) 肽和使用方法
EP1937723B1 (en) Modified chaperonin 10
JP7804672B2 (ja) ペプチドおよび使用方法
WO2026030798A1 (en) Treatment methods for autoimmune diseases
CN116507352A (zh) 冠状病毒的疗法
AU2006287120A1 (en) Modified chaperonin 10

Legal Events

Date Code Title Description
SREP Specification republished